CHAMPIONS ONCOLOGY, INC.(CSBR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,620 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CSBR
Events flagged as statistical outliers against CSBR's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-07-27
CSBR quality score dropped 24 points (54→31) on a new filing
View source filing →
CSBR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for CHAMPIONS ONCOLOGY, INC. (CSBR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CSBR at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,620 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.3) and revenue scale (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CHAMPIONS ONCOLOGY, INC. reports quarterly revenue of $15.2M, net income of $-426.0K, an operating margin of -2.7%. Top institutional holders of CSBR by reported 13-F value include Battery Management, NEA Management Company, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CSBR trades on the Nasdaq exchange and files with the SEC under CIK 771856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CSBR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHAMPIONS ONCOLOGY, INC. directly from SEC EDGAR. CHAMPIONS ONCOLOGY, INC.'s 13F Pro composite quality score has ranged between 17 and 56 since 2021, currently 26.5 — a declining long-term trajectory across 69 quarterly and live scoring snapshots.
Revenue
Q2 2026
$15.2M
Net Income
Q2 2026
$-426.0K
Free Cash Flow
Q2 2026
$-547.0K
Operating Margin
Q2 2026
-2.7%
ROIC
Q2 2026
-42.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+4.4% YoYNet Income
-125.0% YoYOperating Income
-125.0% YoYEPS (Diluted)
-124.2% YoYTotal Assets
-16.6% YoYOp. Cash Flow
-160.5% YoYFree Cash Flow
-172.0% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $59.4M +4.4% | $56.9M +13.5% | $50.2M -6.9% | $53.9M +9.7% | $49.1M +19.7% | $41.0M |
| Net Income | $-1.2M -125.0% | $4.7M +164.6% | $-7.3M -36.4% | $-5.3M -1073.5% | $548.0K +51.4% | $362.0K |
| Operating Income | $-1.1M -125.0% | $4.6M +161.9% | $-7.4M -40.0% | $-5.3M -965.9% | $607.0K +65.8% | $366.0K |
| EPS (Diluted) | $-0.08 -124.2% | $0.33 +161.1% | $-0.54 -38.5% | $-0.39 -1075.0% | $0.04 +100.0% | $0.02 |
| Total Assets | $27.0M -16.6% | $32.3M +23.8% | $26.1M -23.8% | $34.3M -3.0% | $35.4M +28.2% | $27.6M |
| Operating Cash Flow | $-4.5M -160.5% | $7.4M +220.4% | $-6.1M -254.5% | $4.0M -38.9% | $6.5M +486.5% | $-1.7M |
| Free Cash Flow | $-5.0M -172.0% | $7.0M +200.3% | $-7.0M -733.9% | $1.1M -73.3% | $4.1M +182.9% | $-5.0M |
Get alerted when CSBR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CHAMPIONS ONCOLOGY, INC. including:
Top Institutional Holders of CSBR
Battery Management Corp.
$14.9M2,421,673 shNEA Management Company, LLC
$10.6M1,713,720 shVANGUARD CAPITAL MANAGEMENT LLC
$1.9M301,353 shTOCQUEVILLE ASSET MANAGEMENT L.P.
$1.8M295,658 shMORGAN STANLEY
$1.5M235,400 shBANK OF AMERICA CORP /DE/
$1.3M214,058 shRENAISSANCE TECHNOLOGIES LLC
$856.5K139,039 shBlackRock, Inc.
$799.9K129,848 shMink Brook Asset Management LLC
$685.8K111,338 shGEODE CAPITAL MANAGEMENT, LLC
$470.1K76,300 sh
| Fund | Value | Shares |
|---|---|---|
| Battery Management Corp. | $14.9M | 2,421,673 |
| NEA Management Company, LLC | $10.6M | 1,713,720 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.9M | 301,353 |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $1.8M | 295,658 |
| MORGAN STANLEY | $1.5M | 235,400 |
| BANK OF AMERICA CORP /DE/ | $1.3M | 214,058 |
| RENAISSANCE TECHNOLOGIES LLC | $856.5K | 139,039 |
| BlackRock, Inc. | $799.9K | 129,848 |
| Mink Brook Asset Management LLC | $685.8K | 111,338 |
| GEODE CAPITAL MANAGEMENT, LLC | $470.1K | 76,300 |
Companies Similar to CSBR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NATURAL ALTERNATIVES INTERNATIONAL INC
Apyx Medical Corp
FITLIFE BRANDS, INC.
Xtant Medical Holdings, Inc.
BIODESIX INC
Cryoport, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CSBR on your watchlist
Track score changes the day CHAMPIONS ONCOLOGY, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CSBR a good stock to buy?
13F Pro's AI-powered analysis of CHAMPIONS ONCOLOGY, INC. (CSBR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CSBR are available on the CSBR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CSBR is classified as a small company.
Which hedge funds own CSBR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CSBR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CHAMPIONS ONCOLOGY, INC.'s investment landscape.